Intellectual Property India Publishes Patent Application for 'Activin Receptor Type Iib Variants And Uses Thereof' Filed by 35Pharma Inc.

MUMBAI, India, Sept. 12 -- Intellectual Property India has published a patent application (202517069798 A) filed by 35Pharma Inc., Montreal, on July 22, for 'activin receptor type iib variants and uses thereof.'

Inventor(s) include Tremblay, Gilles; Ganesh, Vannakambadi K.; O'Connor-Mccourt, Maureen D.; and Schang, Gauthier.

The application for the patent was published on Sept. 12, under issue no. 37/2025.

According to the abstract released by the Intellectual Property India: "There are provided polypeptides that include an Activin receptor type IIB (ActRIIB) ectodomain (ECD) variant. In some embodiments, a polypeptide of the disclosure includes an ActRIIB-ECD variant fused to an Fc domain moiety. The disclosure also provides pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions associated with TGF superfamily ligand signaling, such as metabolic disorders, diabetes, obesity, cardiometabolic disease, pulmonary hypertension, fibrosis, muscle weakness and atrophy, bone damage, and/or low red blood cell levels (such as anemia)."

The patent application was internationally filed on Dec. 22, 2023, under International application No.PCT/CA2023/051745.

Disclaimer: Curated by HT Syndication.